×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RHHBY – roche holding ltd s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RHHBY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
09:22 am
rhhby
3 High-Yield Dividend ETFs to Buy With $500 and Hold Forever [Yahoo! Finance]
Low
Report
3 High-Yield Dividend ETFs to Buy With $500 and Hold Forever [Yahoo! Finance]
3/20
12:27 pm
rhhby
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025 [Yahoo! Finance]
Low
Report
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025 [Yahoo! Finance]
3/19
09:00 am
rhhby
NRG Oncology and Flatiron Health announce collaboration to leverage leading technology to drive more efficient clinical trials
Low
Report
NRG Oncology and Flatiron Health announce collaboration to leverage leading technology to drive more efficient clinical trials
3/19
07:01 am
rhhby
Roche abandons global diversity targets on concern over U.S. executive orders [CNBC]
Low
Report
Roche abandons global diversity targets on concern over U.S. executive orders [CNBC]
3/19
06:56 am
rhhby
Roche abandons global diversity targets on concern over U.S. executive orders [Yahoo! Finance Canada]
Low
Report
Roche abandons global diversity targets on concern over U.S. executive orders [Yahoo! Finance Canada]
3/13
03:48 pm
rhhby
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal [Yahoo! Finance]
Low
Report
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal [Yahoo! Finance]
3/12
12:37 pm
rhhby
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal [Yahoo! Finance]
Low
Report
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal [Yahoo! Finance]
3/12
10:55 am
rhhby
Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal [Yahoo! Finance]
Low
Report
Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
UPDATE 1-European stock markets calm after pandemic-driven crash [Reuters]
13.0%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
TOP News Decliners
3/12
BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment [Reuters]
-9.0%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: